FDA Announces Recall of Certain Blood Pressure Medication Bottles
People managing high blood pressure often depend on daily medication to keep their condition under control. However, a manufacturing quality issue has prompted a nationwide US recall involving 3,744 bottles of a prescription combination medicine containing three commonly used blood pressure treatments.
The US Food and Drug Administration (FDA) classified the recall on October 26, 2026, after the manufacturer identified problems with the tablets’ ability to dissolve according to required specifications.
The affected medicine is manufactured for Macleods Pharma USA, Inc., based in Princeton, New Jersey. Patients and healthcare professionals are being advised to check the specific lot numbers and National Drug Code (NDC) information to determine whether their medication is included.
Which Blood Pressure Medication Is Being Recalled?
The recall involves Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Tablets 40 mg/10 mg/12.5 mg.
This prescription medication combines three active ingredients used in hypertension treatment. Each component works differently to help manage blood pressure.
Macleods Pharma USA, Inc. initiated the voluntary recall on October 7, 2026. The FDA subsequently classified it as a Class II recall on October 26, 2026.
The recall covers two specific packaging formats:
- 30-tablet bottles: 3,528 bottles, lot number 12251163A, NDC 33342-246-07.
- 90-tablet bottles: 216 bottles, lot number 12251163B, NDC 33342-246-10.
Both affected lots have an expiration date of May 31, 2027. The total number of recalled bottles is 3,744.
Why Was the Medication Recalled?
The FDA identified the reason for the recall as a failure to meet dissolution specifications. This means the affected tablets did not satisfy the required testing standards for how they dissolve.
Dissolution is an important part of medication quality testing. It measures how a tablet releases its active ingredients under specified conditions, helping determine whether the medicine can make those ingredients available for absorption as intended.
If a tablet does not dissolve properly, the amount of medication released may not behave as expected. For a prescription intended to control hypertension, this could potentially affect treatment effectiveness.
The recall is therefore related to a manufacturing quality issue rather than an announcement that all medicines containing these three ingredients are unsafe.
What Does an FDA Class II Recall Mean?
The FDA uses different recall classifications depending on the potential health consequences associated with a product.
A Class II recall means exposure to or use of the affected product may result in temporary or medically reversible health problems. The likelihood of serious adverse health consequences is considered remote under this classification.
This classification is different from a Class I recall, which involves a reasonable probability that using the affected product could cause serious health consequences or death.
It is important to understand that a Class II classification does not mean every patient who used the recalled medication will experience an adverse reaction.
It also does not mean the medication should automatically be considered harmless. Patients who identify an affected bottle should contact their pharmacist or prescribing healthcare professional for instructions.
How to Check Whether Your Medication Is Affected
Patients can begin by examining the prescription bottle and comparing its information with the FDA recall details.
The most important information includes the medication strength, lot number, NDC and expiration date.
Details for 30-Tablet Bottles
- Product: Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Tablets
- Strength: 40 mg/10 mg/12.5 mg
- Package size: 30 tablets
- Lot number: 12251163A
- NDC: 33342-246-07
- Expiration date: May 31, 2027
- Quantity recalled: 3,528 bottles
Details for 90-Tablet Bottles
- Product: Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Tablets
- Strength: 40 mg/10 mg/12.5 mg
- Package size: 90 tablets
- Lot number: 12251163B
- NDC: 33342-246-10
- Expiration date: May 31, 2027
- Quantity recalled: 216 bottles
Remember that the recall concerns the identified lots, not automatically every product containing olmesartan, amlodipine or hydrochlorothiazide.
What Should Patients Do If They Have the Recalled Medication?
Finding a matching lot number is a reason to contact a healthcare professional promptly. Patients should speak with their pharmacist or prescribing doctor to determine the appropriate next step and whether a replacement prescription is necessary.
Do not independently discontinue prescribed blood pressure treatment without medical advice. Abruptly interrupting a treatment plan can leave hypertension inadequately controlled and create additional health risks.
Patients should keep their medication packaging available when contacting their pharmacist. The lot number, NDC and expiration date can help the pharmacy determine whether the specific bottle falls within the recall.
Healthcare professionals can also explain whether an alternative product or another available lot is appropriate for the patient’s treatment needs.
If a patient experiences concerning symptoms or believes their blood pressure is not adequately controlled, they should seek appropriate medical advice rather than attempting to adjust medication doses independently.
Understanding the Three Ingredients in the Recalled Medicine
The recalled combination product contains three active ingredients that work through different mechanisms to help manage high blood pressure.
Olmesartan Medoxomil
Olmesartan medoxomil belongs to a group of medicines called angiotensin II receptor blockers (ARBs). It works by blocking the effects of angiotensin II, a substance that causes blood vessels to narrow.
By helping blood vessels relax, the medicine supports lower blood pressure.
Amlodipine
Amlodipine is a calcium channel blocker. It helps relax blood vessels by reducing calcium movement into certain muscle cells in blood vessel walls.
This allows blood vessels to widen, helping blood circulate more easily.
Hydrochlorothiazide
Hydrochlorothiazide is a thiazide diuretic, sometimes referred to as a water pill. It helps the kidneys remove additional salt and water through urine.
Reducing excess fluid in the body can help lower blood pressure.
Combining these ingredients allows the medication to address hypertension through different mechanisms. However, the affected lots remain subject to the recall because of their reported dissolution testing failure.
Does the Recall Affect Every Blood Pressure Medication?
No. The recall should not be interpreted as applying to every medicine used to treat hypertension.
It specifically identifies the 40 mg/10 mg/12.5 mg combination product manufactured for Macleods Pharma USA, Inc., and the two affected lot numbers.
Other strengths, manufacturers and production lots should not automatically be considered part of this recall.
This distinction matters because several different prescription medicines contain similar active ingredients. A patient taking a medication with the same ingredients may have a different manufacturer, packaging format or lot number.
The safest approach is to compare the exact product information with the FDA recall record rather than relying on the medicine’s name alone.
Where to Find Official FDA Recall Information
The FDA publishes drug recall information through its official website and Enforcement Reports. These records help patients, pharmacists and healthcare providers identify affected products and understand why a manufacturer has initiated a recall.
For this particular recall, patients can search for Macleods Pharma USA, Inc., and the product name in the FDA’s drug recall and enforcement information.
Additional assistance may be available through the pharmacy that dispensed the medication or the prescribing healthcare provider.
Patients outside the United States should also check with their national medicines regulatory authority before assuming that a US recall affects products sold in their country. Product registration, distribution and affected batches can differ between markets.
What Happens Next in the Medication Recall?
The recall highlights the importance of pharmaceutical manufacturing standards and quality testing, particularly for medicines intended for long-term treatment of chronic conditions.
Macleods Pharma USA’s voluntary recall and the FDA’s Class II classification provide a specific identification process for the affected bottles. Patients can use the lot and NDC information to establish whether their medication is included.
For now, anyone with a potentially affected prescription should contact a pharmacist or healthcare provider, confirm the product details and ask about an appropriate replacement or further instructions.
Patients should also monitor official FDA updates for additional information about the recall and any changes to the manufacturer’s instructions.
Checking the lot number is a simple but important step. For people who rely on daily hypertension treatment, confirming that their medication is not part of an affected batch can help them make informed decisions while maintaining continuity of care.
